Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase 3 11Phase 1/2 10Phase 1 8Phase NA 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 27Vincristine 24Dexamethasone 22Rituximab 21Methotrexate 21Cytarabine 21Mercaptopurine 16Doxorubicin 15Etoposide 13Asparaginase 13Daunorubicin 12Prednisone 10Prednisolone 10Granulocyte Colony-Stimulating Factor 10Ifosfamide 8Idarubicin 8fludarabine 7pegylated granulocyte colony-stimulating factor 6Thioguanine 6Teniposide 6Vindesine 5Brentuximab Vedotin 5ibrutinib 4fludarabine phosphate 4Stem Cell Transplantation 4Gemcitabine 4Cisplatin 4Aprepitant 4zanubrutinib 3prednylidene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × ibritumomab tiuxetan × Lymphoid × Clear all
NCT00168727 2023-08-23

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Biogen

Phase 4 Completed
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡